AM095 free acid is a potent LPA1 receptor antagonist. AM095 free acid inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, respectively.
AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. AM095 dose-dependently reduces LPA-stimulated histamine release.
| Molecular Weight | 456.49 |
| Formula | C27H24N2O5 |
| CAS Number | 1228690-36-5 |
| Solubility (25°C) | DMSO: ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related LPL Receptor Products |
|---|
| BMS-986234
BMS-986234 is a lysophosphatidic acid receptor-1 (LPA1) antagonist with a Kb value of 2.8 ± 0.4 nM. |
| BMS-986337
BMS-986337 is a lysophosphatidic acid receptor (LPAR1) antagonist for studies related to pulmonary fibrosis. |
| DJS-002
DJS-002 is an LPA1 receptor antagonist that may be used in studies related to idiopathic pulmonary fibrosis (IPF). |
| HL001
HL001 is an LPA1 receptor antagonist that may be used in studies related to idiopathic pulmonary fibrosis (IPF). |
| LTSE-2578
LTSE-2578 is an LPA1 receptor antagonist that may be used in studies related to idiopathic pulmonary fibrosis (IPF). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
